Wilms tumor treatment was once organized primarily around stage.
AREN2231 is testing a more complex model.
This episode examines how the Children’s Oncology Group is integrating anatomic stage with molecular biology and treatment response to determine who may need less therapy, who may need different therapy, and who may require intensification.
We explore 1q gain, combined loss of heterozygosity at 1p and 16q, the specific role of 11p15, post-chemotherapy blastemal predominance, and the major de-escalation and escalation questions being tested in AREN2231.
The episode also explains why prognostic biomarkers are not automatically predictive biomarkers, why trial questions should not be mistaken for established standards, and why precision Wilms therapy begins in the operating room with accurate staging, lymph-node sampling, and adequate tissue for central pathology and molecular testing.
The central framework is simple:
Anatomy tells us where the tumor is.
Biology estimates its intrinsic risk.
Response tells us what survived treatment.
Amin AfrasiabiHost